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Abstract
Sulbactam/ampicillin （SBT / ABPC） and ceftriaxone （CTRX） are the initial antibiotics 
recommended for treating aspiration pneumonia without risk factors for drug-resistant pathogens.  
However, the condition of some patients does not improve with these antibiotics.  Therefore, 
we investigated the new risk factors associated with failure of initial antibiotic treatment in 
patients with aspiration pneumonia. This study included 487 patients diagnosed with aspiration 
pneumonia who received initial antibiotic treatment with SBT / ABPC or CTRX, and were 
hospitalized at the Respiratory Medicine Department of the Yokohama City Minato Red Cross 
Hospital.  The outcome was initial antibiotic treatment failure, which was defined as a change 
from initial to secondary antibiotic treatment.  The characteristics of patients with and without 
antibiotic treatment failure were compared using univariate analyses, and significant independent 
risk factors for the initial antibiotic treatment failure were selected using multivariate analyses. 
The mean age of the patients was 84.1± 9.6 years; 302 （62％） of them were men and 
93 patients experienced antibiotic treatment failure.  Logistic regression analysis extracted no 
restriction of diet on admission （odds ratio ［OR］, 3.23; 95% confidence interval ［CI］, 1.35-
7.74）, history of hospitalization due to aspiration pneumonia （OR, 1.81; 95％CI, 1.12-2.93）, 
the severity of pneumonia （OR, 1.37; 95％CI, 1.01-1.86）, and C-reactive protein （CRP） level 
（OR, 1.26; 95％CI, 1.09-1.45） as risk factors for initial antibiotic treatment failure. Our results 
suggested that no restriction of diet on admission, history of hospitalization due to aspiration 
pneumonia, severity of pneumonia, and increased CRP levels were the risk factors associated 
with failure of initial antibiotic treatment in patients with aspiration pneumonia.  These factors 
will be useful for determining an effective initial treatment strategy for patients with aspiration 
pneumonia.
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treatment failure, initial antibiotic treatment
Introduction
　Aspiration pneumonia in a patient with a pre-
dis po si tion to aspiration is caused by dysphagia1. 
Previously published data demonstrated that 66.8％ of 
patients hospitalized for pneumonia were diagnosed 
with aspiration pneumonia2; aspiration pneumonia 
accounted for 80.1％ and 95％ of the cases among 
those aged ≥ 70 years and ≥ 90 years, respectively. 
Therefore, most patients hospitalized with pneu mo-
nia have the aspiration type, and this proportion 
is increased among older patients.  Aspiration 
pneumonia is associated with increased severity, 
high rates of in-hospital mortality and recurrent 
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pneumonia3, 4, and poor prognosis.
　Pneumonia is classified into three types: community-
acquired pneumonia, hospital-acquired pneumonia, 
and healthcare-associated pneumonia （HCAP）.  In 
Japan, HCAP is classified as nursing-and healthcare-
associated pneumonia （NHCAP）, based on the 
Japanese medical system.  Most patients with NHCAP 
are older and have aspiration pneumonia5, 6, and the 
treatment of these patients is performed based on the 
NHCAP treatment guidelines7.
　Aspiration pneumonia is often caused by Strep-
to coc cus pneumoniae, Staphylococcus aureus, and 
anaerobic bacteria.  However, in addition to these 
bacteria, drug-resistant pathogens such as methicillin-
resistant Staphylococcus aureus （MRSA）, Pseudomonas 
aeruginosa, Acinetobacter, and extended-spectrum 
β-lactamase-producing enteric bacteria have been 
included as causative agents.  The isolation rate of 
drug-resistant pathogens has been reported as 11％ 
in patients with NHCAP and 3％-54.4％ in patients 
with aspiration pneumonia4, 6, 8.  Therefore, antibacterial 
agents effective against these bacteria are used for 
initial antibiotic treatment.  The initial antibiotic 
treatment was determined while considering the risk 
factors for drug-resistant pathogens based on the 
clinical practice guideline for NHCAP7.  These risk 
factors included “history of antibiotic treatment for 2 
or more days in the preceding 90 days,” or “current 
tube feeding,” or “history of MRSA isolation”7. 
Broad-spectrum antibiotics or anti-MRSA agents are 
recommended when patients have a minimum of 
one of these risk factors.  In contrast, treatment with 
sulbactam/ampicillin （SBT / ABPC） or ceftriaxone 
（CTRX） is recommended as the initial antibiotic 
treatment for patients without these risk factors.
　The conditions of some patients do not improve 
after treatment with SBT/ABPC or CTRX.  Since 
aspiration pneumonia is common in older people 
with underlying diseases and poor physical 
conditions, risk factors other than those9-14 for drug-
resistant pathogens may be involved.  However, 
these factors have not been investigated so far. 
The initial treatment of aspiration pneumonia is 
important because initial treatment failure is one 
of the independent prognostic factors in patients 
with aspiration pneumonia8.  Therefore, we aimed 
to investigate the risk factors for initial antibiotic 
treatment failure in patients with aspiration pneu mo-
nia, other than those for drug-resistant pathogens, to 
identify new factors that might help to determine the 
initial antibiotic treatment.
Methods
Study design and patient population
　This study included 489 patients diagnosed with 
aspiration pneumonia who received initial antibiotic 
treatment with SBT / ABPC or CTRX and were 
hospitalized at the Respiratory Medicine Department 
of the Yokohama City Minato Red Cross Hospital 
in Japan, between January 2012 and March 2017. 
Two patients who were not classified as NHCAP 
and presented with other infections were excluded. 
Finally, data of 487 patients were analyzed for this 
study.  This study was approved by the clinical 
committee of the Yokohama City Minato Red Cross 
Hospital （Permit Number: 2017-42）.
Data collection
　The following data were collected from the medical 
records of the patients at baseline and before 
admission.  The investigation items before admission 
included meal route, aspiration episode, history of 
hospitalization due to aspiration pneumonia, activities 
of daily living （ADL）, residence, the number of 
NHCAP criteria met7, and risk factors for drug-
resistant pathogens7.  The specificity （22％） and 
positive predictive values （17％） of the risk factors 
for drug-resistant pathogens are low15.  To validate 
the accuracy of previously reported risk factors for 
drug-resistant pathogens, we also analyzed patients 
with drug-resistant pathogens.  Items investigated 
on admission were age, sex, body weight, height, 
body mass index, body temperature, respiratory 
rate, pulse oximetric saturation, systolic blood 
pressure, C-reactive protein （CRP） level, white 
blood cells, albumin, creatinine （Crea）, and blood 
urea nitrogen （BUN） levels, past medical history/
comorbidities （cerebrovascular disease, neuromuscular 
disease, dementia, chronic obstructive pulmonary 
disease, a gastrointestinal disease associated with 
gastroesophageal reflux, cancer, and / or diabetes 
mellitus）, severity of pneumonia, diet restriction, type 
of initial antibiotics, and the numbers and types of 
medications.  The severity of pneumonia was assessed 
using the following parameters: age, dehydration, 
respiration, orientation, and pressure （A-DROP） 
score16, and was classified as mild, moderate, severe, 
and very severe.  Investigation items during admission 
were intervention by a speech therapist, intervention 
by a dentist, length of hospitalization, duration 
of fasting, duration of initial antibiotic, types of 
secondary antibiotics, and in-hospital mortality rate.




　NHCAP was defined as patients who met a 
minimum of one of the following criteria7: resident of 
an extended care facility or nursing home; discharged 
from a hospital within the preceding 90 days; an 
elderly or disabled person receiving nursing care 
（performance status ≥ 3）; and an outpatient receiving 
regular endovascular treatment （dialysis, antibiotic 
therapy, chemotherapy, or immunosuppressant 
therapy）.  The risk factors for drug-resistant 
pathogens7 were history of antibiotic treatment for 
≥ 2 days in the preceding 90 days, current tube 
feeding, and history of MRSA isolation.  The ADL 
was evaluated using the “Criteria for determination of 
the daily life independence level （bedridden level） of 
the older with a disability”17.  Medication details were 
collected from the medical records of the patients 
（excluding medicine taken only when necessary）, and 
the category of drugs was classified based on the 
Therapeutic Category of Drugs in Japan （Standard 
Commodity Classification of Japan “division 87-dugs 
and related commodities”） posted on the Kyoto 
Encyclopedia of Genes and Genomes website.
Outcome
　The outcome was the failure of initial antibiotic 
treatment.  This was defined as a change from initial 
antibiotics to secondary antibiotics （meropenem 
［MEPM］, doripenem ［DRPM］, tazobactam/piperacillin 
［TAZ / PIPC］, cefepime ［CFPM］ plus clindamycin 
［CLDM］, ciprofloxacin ［CPFX］ plus SBT / ABPC, 
or vancomycin ［VCM］）, which can effectively act on 
patients with risk factors for drug-resistant pathogens. 
Death was not included as a factor of initial 
antibiotic treatment failure because it could have 
been caused by factors other than initial antibiotic 
treatment failure.
Statistical analysis
　The characteristics of patients with and without 
antibiotic treatment failure were compared using 
the Chi-squared test or Fisher’s exact test for 
categorical variables; the Mann—Whitney U test or 
Student’s t-test was used for continuous variables. 
The severity of pneumonia was classified as mild 
and moderate, severe, and very severe, according 
to the patient’s A-DROP scores.  Variables with a 
p-value of ＜ 0.1 extracted through the univariate 
analysis were applied to the multivariate analysis. 
We confirmed that these variables did not correlate 
with each other.  Multivariate analysis of the risk 
factors for initial antibiotic treatment failure in 
patients with aspiration pneumonia was performed 
using the stepwise selection method.  In addition, the 
relationship between initial antibiotic treatment failure 
and medications at admission were evaluated using 
the univariate and multivariable analyses.  All data 
were analyzed using SPSS software version 25 （IBM 




　The characteristics of patients before, on, and 
during admission are shown in Table 1.  The mean 
age was 84.1 ± 9.6 years and 302 （62％） of them 
were men.  The types of initial antibiotic treatment 
included SBT / ABPC （91.8％） and CTRX （8.2％）. 
A history of hospitalization due to aspiration 
pneumonia was observed in 167 （34.4％） patients. 
Severe and very severe aspiration pneumonia was 
observed for 244 （50.1％） of the total patients. 
Older or disabled people receiving nursing care 
accounted for 483 （99.2％） of the total patients.  The 
risk factors for drug-resistant pathogens were observed 
in 219 （45％） of the total patients.
Outcome
　Ninety-three patients experienced failure of initial 
antibiotic treatment.  The secondary antibiotics used 
were MEPM monotherapy （44 patients）, DRPM 
monotherapy （9 patients）, TAZ/PIPC monotherapy 
（20 patients）, CFPM plus CLDM （2 patients）, CPFX 
plus SBT/ABPC （2 patients）, and VCM monotherapy 
or combination therapy （16 patients）.
　Patients with initial antibiotic treatment failure 
had a significantly longer duration of hospitalization 
than those without initial antibiotic treatment failure 
（median 25 days ［8.0-196 days］ vs. 17 days ［1.0-126 
days］; P ＜ 0.01）.  The rate of in-hospital mortality 
was significantly higher in patients with initial 
antibiotic treatment failure than in those without 
initial antibiotic treatment failure （25.8％ vs. 9.4％; P 
＜ 0.01）.
Characteristics of patients with antibiotic treatment 
failure analyzed using univariate analysis
　Table 2 shows the results of the univariate 
analysis.  The proportion of males, meal intake on 
admission, and rate of high severity of pneumonia 
were significantly higher in patients with treatment 
failure than in those without treatment failure. 
Additionally, the levels of CRP, BUN, and Crea were 
significantly higher in patients with treatment failure 
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Table 1.   Patient characteristics
Characteristics Total（n＝487）
Investigation item on admission
Age （years） 84.1± 9.6
Sex, male 302 （62）
Body weight （kg） 42 （21.3-77.4）
Height （cm） 155.8± 10.4
BMI （kg/m2） 18.1± 4.0
Body temperature （℃） 37.4± 0.9
Respiratory rate （times） 22 （11-57）
SpO2 （％） 88 （40-99）
WBC （×102/µl） 105 （12-395）
CRP （mg/dl） 6.5 （0-38.1）
BUN （mg/dl） 22.5 （4.7-164.3）
Crea （mg/dl） 0.71 （0.15-7.14）
Alb （g/dl） 3.2± 0.5
Systolic blood pressure （mmHg） 124.2± 24.5
Past medical history / comorbidities 
 Cerebrovascular disease 174 （35.7）
 Neuromuscular disease  69 （14.2）
 Dementia 210 （43.1）
 COPD 48 （9.9）
 Gastrointestinal disease associated with gastroesophageal reflux                   38 （7.8）
 Cancer 126 （25.9）
 Diabetes  92 （18.9）
No restriction of diet 26 （5.3）
The severity of pneumonia
 Mild / Moderate / Severe / Very severe 4 （0.8）/ 239 （49.1）/ 160 （32.9）/ 84 （17.2）
Drug-resistant pathogensa 115 （23.6）
Type of initial antibiotic
SBT / ABPC / CTRX 447 （91.8）/ 40 （8.2）
Investigation item before admission
Meal route
 Oral / Tubal feeding / Infusion 430 （88.3）/ 58 （11.9）/ 6 （1.2）
Aspiration episode 196 （40.2）
History of hospitalization due to aspiration pneumonia                        167 （34.3）
ADLb
 Rank J / A / B / C 5 （1.0）/ 44 （9.0）/ 173 （35.5）/ 265 （54.4）
Residence
 Home / Care facility or nursing home 285 （58.7）/ 201 （41.3）
Definition of NHCAPa
 Resident of an extended care facility or nursing home 198 （40.7）
 Discharge from a hospital within the preceding 90 days                         129 （26.5）
 An elderly or the disabled person receiving nursing carec                       483 （99.2）
 Person who is receiving regular endovascular treatment as an outpatientd            23 （4.7）
Risk factors for drug-resistant pathogensa
 History of antibiotic therapy for 2 or more days in the preceding 90 days          180 （37.0）
 Current tube feeding  64 （13.1）
 History of MRSA isolation 39 （8.0）
Investigation item during admission
Intervention by a speech therapist 298 （61.2）
Intervention by a dentist 110 （22.6）
Length of initial antibiotic treatment （day） 8 （1-31）
Length of hospitalization （day） 18 （1-196）
The fasting duration （day） 4 （0-62）
n （％） or mean ± standard deviation （SD） or median （range）
SBT / ABPC, sulbactam / ampicillin; CTRX, ceftriaxone; MRSA, methicillin-resistant Staphylococcus aureus; 
COPD, chronic obstructive pulmonary disease; TPN, total parenteral nutrition; NHCAP, nursing-and healthcare-
associated pneumonia; BMI, body mass index; WBC, white blood cells; CRP, C-reactive protein; BUN, blood 
urea nitrogen; Crea, creatinine; Alb, albumin; SpO2, pulse oximetric saturation; ADL, activities of daily living
a：Clinical practice guidelines for NHCAP
b：Criteria for determination of the daily life independence level （bedridden level） of the elderly with disability
c：Patients whose performance status is performance status 3 （capable of only limited self-care, confined to 
a bed or a chair, more than 50% of their waking hours） or more
d：dialysis, antibiotic therapy, chemotherapy, immunosuppressant therapy
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Investigation item on admission
Age （years） 84.0± 10.0 84.6± 7.8 0.637
Sex, male 234 （59） 68 （73） 0.014
Body weight （kg） 42.1 （21.3-77.4） 41.0 （30-65.5） 0.810
Height （cm） 155.5± 10.4 156.8± 10.1 0.399
BMI （kg/m2） 18.2± 4.2 17.8± 3.2 0.632
Body temperature （℃） 37.4± 0.9 37.5± 1.0 0.350
Respiratory rate （times） 23.0 （11-50） 22.0 （13-57） 0.244
SpO2 （%） 88.0 （40-99） 87.0 （54-99） 0.627
WBC （×102/µl） 105.0 （12-395） 102.0 （24-288） 0.304
CRP （mg/dl） 6.2 （0-38.1） 7.3 （0.1-35） 0.020
BUN （mg/dl） 22.0 （4.7-164.3） 24.8 （7.2-85.8） 0.024
Crea （mg/dl） 0.7 （0.15-7.14） 0.8 （0.22-6.14） 0.022
Alb （g/dl） 3.2± 0.5 3.1± 0.5 0.137
Systolic blood pressure （mmHg） 123.2± 24.2 128.4± 25.0 0.064
Past medical history / comorbidities
 Cerebrovascular disease 142 （36.0） 32 （34.4） 0.768
 Neuromuscular disease  54 （13.7） 15 （16.1） 0.547
 Dementia 177 （44.9） 33 （35.5） 0.098
 COPD 37 （9.4） 11 （11.8） 0.478
 Gastrointestinal disease associated with gastroesophageal reflux　　29 （7.4） 9 （9.7） 0.454
 Cancer 105 （26.6） 21 （22.6） 0.420
 Diabetes  72 （18.3） 20 （21.5） 0.474
No restriction of diet 17 （4.3） 9 （9.7） 0.041
The severity of pneumonia 0.013
 Mild & Moderate 208 （53） 35 （38）
 Severe 118 （30） 42 （45）
 Very severe  68 （17） 16 （17）
Investigation item before admission
Meal route
 Oral 348 （88.3） 82 （88.2） 0.967
 Tubal feeding  46 （11.7） 11 （11.8） 0.978
 Infusion 6 （1.5） 0 （0） 0.278
Aspiration episode 158 （40.1） 38 （40.9） 0.893
History of hospitalization due to aspiration pneumonia 128 （32.5） 39 （41.9） 0.084
ADLa 0.714
 Rank J  5 （1.3） 0 （0）
 Rank A 34 （8.6） 10 （10.8）
 Rank B 139 （35.3） 34 （36.6）
 Rank C 216 （54.8） 49 （52.7）
Residence 0.564
 Home 228 （58.1） 57 （61.3）
 Care facility or nursing home 165 （41.9） 36 （38.7）
Definition of NHCAPb
 Resident of an extended care facility or nursing home 162 （41.1） 36 （38.7） 0.671
 Person who has been discharged from a hospital within the preceding 90 days  103 （26.1） 26 （28.0） 0.721
 An elderly or disabled person who is receiving nursing carec 391 （99.2） 92 （98.9） 0.573
 Person who is receiving regular endovascular treatment as an outpatientd 19 （4.8） 4 （4.3） 0.544
Risk factors for drug-resistant pathogensb
 History of antibiotic therapy for 2 or more days in the preceding 90 days 142 （36.0） 38 （40.9） 0.386
 Current tube feeding  53 （13.5） 11 （11.8） 0.677
 History of MRSA isolation 31 （7.9） 8 （8.6） 0.815
n （％） or mean ± SD or median （range）
COPD, chronic obstructive pulmonary disease; TPN, total parenteral nutrition; MRSA, methicillin-resistant 
Staphylococcus aureus; NHCAP, nursing-and healthcare-associated pneumonia; BMI, body mass index; WBC, 
white blood cells; CRP, C-reactive protein; BUN, blood urea nitrogen; Crea, creatinine; Alb, albumin; SpO2, pulse 
oximetric saturation; ADL, activities of daily living
a：Criteria for determination of the daily life independence level （bedridden level） of the elderly with disability
b：Clinical practice guidelines for NHCAP
c：Patients whose performance status is performance status 3（capable of only limited self-care, confined to a 
bed or a chair, more than 50％ of their waking hours） or more
d：dialysis, antibiotic therapy, chemotherapy, immunosuppressant therapy
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when compared to those in patients without treatment 
failure.
Multivariable analysis of the risk factors for initial 
antibiotic treatment failure
　Multivariable logistic regression analysis was 
performed using the following variables: dementia, 
the severity of pneumonia, history of hospitalization 
due to aspiration pneumonia, levels of CRP and 
Crea, and no restriction of diet on admission.  Sex, 
BUN, and systolic blood pressure are included in the 
A-DROP; hence, these factors were excluded from the 
multivariable analysis.  The significant, independent 
risk factors for antibiotic treatment failure in patients 
with aspiration pneumonia included the following: 
severity of pneumonia （odds ratio ［OR］, 1.37; 
95％ confidence interval ［CI］, 1.01-1.86）, history of 
hospitalization due to aspiration pneumonia （OR, 1.81; 
95％CI, 1.12-2.93）, no restriction of diet on admission 
（OR, 3.23; 95％CI, 1.35-7.74）, and CRP levels （OR, 
1.26; 95％CI, 1.09-1.45; Table 3）.
Medications at admission associated with initial 
antibiotic treatment failure
　In the univariate analysis, the use of antacids, 
other agents affecting the digestive organs, urinary 
disturbance agents other than overactive bladder 
agents, and anti-tubercular agents at admission 
were significantly higher in patients with treatment 
failure than in those without treatment failure 
（Table 4）.  The multivariable analysis was performed 
using dementia, severity of pneumonia, history of 
hospitalization due to aspiration pneumonia, CRP 
and Crea levels, no restriction of diet on admission, 
urinary disturbance agents other than overactive 
bladder agents, antacids, other agents affecting the 
digestive organs, anti-tubercular agents, sex hormone 
preparations, and other agents related to blood and 
body fluids （antiplatelet agents）.  The significant 
independent risk factors for initial antibiotic treatment 
failure in patients with aspiration pneumonia were 
history of hospitalization due to aspiration pneumonia 
（OR, 1.79; 95％CI, 1.10-2.90）, no restriction of diet on 
admission （OR, 3.26; 95％ CI, 1.36-7.81）, CRP level 
（OR, 1.28; 95％CI, 1.10-1.47）, and urinary disturbance 
agents other than overactive bladder agents （OR, 
2.56; 95％CI, 1.34-4.88） （Table 5）.  In this study, 
the urinary disturbance agents other than overactive 
bladder agents included urapidil, tamsulosin, silodosin, 
naftopidil, and Chimaphila umbellata extract, Populus 
tremula extract, Pulsatilla pratensis mill extract, 
Equisetum arvense extract, and wheat germ oil.
Discussion
　We investigated the risk factors for initial 
antibiotic treatment failure in patients with aspiration 
pneumonia other than those for drug-resistant 
pathogens, to identify new factors that would help 
to determine the initial treatment.  The severity of 
pneumonia, history of hospitalization due to aspiration 
pneumonia, no restriction of diet on admission, and 
CRP levels were identified as significant independent 
risk factors for initial antibiotic treatment failure in 
this study.
　To date, the study of risk factors has focused 
on drug-resistant pathogens9-14.  Since aspiration 
pneumonia is common in older adults with underlying 
diseases and poor physical conditions, we assumed 
that unknown risk factors, other than those for drug-
resistant pathogens, might be involved.  Our findings 
strongly suggested that the diet status, deterioration 
of the general condition of the patient, and intensity 
of inflammation in the lung tissues are factors that 
will prove beneficial when determining the therapeutic 
strategy.  Thus, taking these factors along with the 
currently existing risk factors into account might help 
Table 3.   Multivariable analysis of risk factors for initial antibiotic treatment failure
Factors β OR 95％CI p-value
The severity of pneumonia Mild vs Moderate vs  Severe vs Very severe 0.31 1.37 1.01-1.86 0.045
History of hospitalization due to  
aspiration pneumonia No vs Yes 0.59 1.81 1.12-2.93 0.016
No restriction of diet on admission No vs Yes 1.17 3.23 1.35-7.74 0.008
CRP （mg/dl） 5 mg/dl 0.23 1.26 1.09-1.45 0.002
CRP, C-reactive protein; OR, odds ratio; CI, confidence interval.
Dementia, severity of pneumonia, history of hospitalization due to aspiration pneumonia, CRP, Crea, and no restriction 
of diet on admission were incorporated into the multivariable analysis.
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Table 4.   Medications at admission that were associated with antibiotic treatment failure
medications Patients without treatment failure n＝394
Patients with treatment 
failure n＝93 p-value
Number of medications   5 （0-16）  6 （0-18） 0.261
Agents affecting central nervous system 231 （58.6） 52 （55.9） 0.633
　Hypnotics and sedatives, antianxiety drugs  61 （15.5） 18 （19.4） 0.362
　Antiepileptics  30 （7.6）  7 （7.5） 0.977
　Antipyretics, analgesics, and anti-inflammatory agents　　　　　　 23 （5.8）  6 （6.5） 0.822
　Antiparkinsonism agents  31 （7.9） 12 （12.9） 0.124
　Psychotropic agents 116 （29.4） 26 （28.0） 0.777
　Agents used for common cold   1 （0.3）  0 （0） 0.809
　Other agents affecting central nervous system  93 （23.6） 24 （25.8） 0.655
Agents affecting peripheral nervous system   9 （2.3）  4 （4.3） 0.223
　Skeletal muscle relaxants   1 （0.3）  0 （0） 0.809
　Autonomic agents   6 （1.5）  2 （2.2） 0.471
　Antispasmodics   2 （0.5）  2 （2.2） 0.166
Antimotion sickness agents   6 （1.5）  1 （1.1） 0.601
Cardiovascular agents 238 （60.4） 55 （59.1） 0.822
　Cardiotonics  15 （3.8）  3 （3.2） 0.539
　Antiarrhythmic agents  16 （4.1）  4 （4.3） 0.551
　Diuretics  91 （23.1） 17 （18.3） 0.315
　Antihypertensives 108 （27.4） 29 （31.2） 0.467
　Vasoconstrictors   2 （0.5）  0 （0） 0.654
　Vasodilators  97 （24.6） 26 （28.0） 0.505
　Agents for hyperlipidemias  63 （16.0） 14 （5.1） 0.824
　Other cardiovascular agents  27 （6.9）  6 （6.5） 0.890
Agents affecting respiratory organs  96 （24.4） 22 （23.7） 0.886
　Antitussives   3 （0.8）  1 （1.1） 0.573
　Expectorants  77 （19.5） 21 （22.6） 0.511
　Antitussives and expectorants   1 （0.3）  0 （0） 0.809
　Bronchodilators  22 （5.6）  2 （2.2） 0.130
Agents affecting digestive organs 254 （64.5） 66 （71.0） 0.235
　Antidiarrheals, intestinal regulators  40 （10.2） 11 （11.8） 0.635
　Agents for peptic ulcer 173 （43.9） 44 （47.3） 0.553
　Stomachics and digestives   4 （1.0）  1 （1.1） 0.655
　Antacids   0 （0）  2 （2.2） 0.036
　Purgatives and clysters 142 （36.0） 36 （38.7） 0.631
　Cholagogues  14 （3.6）  1 （1.1） 0.185
　Other agents affecting digestive organs  29 （7.4） 14 （15.1） 0.019
Hormone preparations  23 （5.8）  9 （9.7） 0.179
　Thyroid and para-thyroid hormone preparations  11 （2.8）  2 （2.2） 0.534
　Adrenal hormone preparations  11 （2.8）  4 （4.3） 0.317
　Sex hormone preparations   3 （0.8）  3 （3.2） 0.087
Urinary disturbance agents other than overactive bladder agents　 　 36 （9.1） 17 （18.3） 0.011
Vitamin preparations  68 （17.3） 15 （16.1） 0.794
Nutrients, tonics and alteratives  47 （11.9） 10 （10.8） 0.751
　Calcium compounds and preparations   5 （1.3）  0 （0） 0.345
　Mineral preparations  42 （10.7） 10 （10.8） 0.979
Agents relating to blood and body fluids 136 （34.5） 35 （37.6） 0.571
　Hemostatics   2 （0.5）  0 （0） 0.654
　Anticoagulants  42 （10.7）  8 （8.6） 0.556
　Other agents relating to blood and body fluids  98 （24.9） 31 （33.3） 0.096
Other agents affecting metabolism 107 （27.2） 24 （25.8） 0.792
　Agents for liver disease   2 （0.5）  0 （0） 0.654
　Agents for treatment of gout  57 （14.5） 14 （15.1） 0.885
　Antidiabetic agents  40 （10.2） 13 （14.0） 0.287
　Other agents affecting metabolism  23 （5.8）  2 （2.2） 0.112
Antineoplastic agents  12 （3.0）  5 （5.4） 0.209
Antiallergic agents  44 （11.2） 10 （10.8） 0.909
　Antihistamines   3 （0.8）  2 （2.2） 0.244
　Agents for stimulation therapy   3 （0.8）  1 （1.1） 0.573
　Other antiallergic agents  40 （10.2）  7 （7.5） 0.441
Crude drug and Chinese medicine formulations  47 （11.9） 17 （18.3） 0.103
Antibiotic preparations  17 （4.3）  4 （4.3） 0.628
Chemotherapeutics   7 （1.8）  3 （3.2） 0.294
　Sulfonamide preparations   0 （0）  1 （1.1） 0.191
　Anti-tuberculous agents   0 （0）  2 （2.2） 0.036
　Synthetic antibacterials   2 （0.5）  0 （0） 0.654
　Other chemotherapeutics   5 （1.3）  0 （0） 0.345
Narcotics   0 （0）  1 （1.1） 0.191
n （%） or mean ± standard deviation （SD） or median （range）
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in deciding an effective initial treatment strategy for 
patients with aspiration pneumonia.  In addition to 
the antibiotic treatment, appropriate management of 
the general condition, such as water management, 
respiratory management, and oral care, will lead to an 
improvement in aspiration pneumonia.
　The risk of treatment failure increased 3.23-
fold in patients without restriction of diet on 
admission.  There are three possible explanations 
for this observation.  Firstly, food residue and ADL 
decrease are significantly associated with an increase 
in bacteria in the saliva of older people requiring 
care18.  Moreover, the swallowing function decreases 
in patients with aspiration pneumonia19.  Based on 
previous findings, we assumed that when a patient 
with impaired swallowing function ingests food on 
admission, it remains in the oral cavity leading to 
an increase in the number of bacteria.  Secondly, 
the pathogens that cause pneumonia colonize on 
the surface of the tongue and promote further 
colonization in the pharynx20.  Aspiration of 
pharyngeal bacteria is the major infection route in the 
development of pneumonia21.  Therefore, pneumonia 
continues owing to bacterial colonization from the 
tongue to the pharynx.  Thirdly, in patients with 
aspiration pneumonia with reduced cough reflex22, 
aspiration may continue.  Therefore, in a patient with 
impaired swallowing function, the ingestion of food 
might increase bacterial colonization in the oral cavity, 
which could move and colonize within the pharynx 
resulting in a lack of therapeutic effects of SBT /
ABPC and CTRX.  Thus, oral care and fasting may 
be beneficial to prevent repeated aspiration to reduce 
ongoing pneumonia by reducing bacteria in the oral 
cavity.
　In a survey conducted by general internal 
physicians and respiratory specialists on fasting as a 
strategy to treat aspiration pneumonia, 89.4％ of the 
clinicians recommended temporary fasting23.  However, 
no studies have reported the benefits of fasting on 
admission.  To the best of our knowledge, this is the 
first study to demonstrate that no restriction of diet 
on admission on admission in patients with aspiration 
pneumonia affected the therapeutic efficacy of 
antibiotic treatment.  Our results strongly suggest that 
it might be necessary to restrict the diet of patients 
with aspiration pneumonia at admission and evaluate 
their swallowing function before resuming their diet.
　The risk of treatment failure increased 1.81-fold 
in patients with a history of hospitalization due to 
aspiration pneumonia.  An increased risk of treatment 
failure may be associated with a history of antibiotic 
treatment.  If there was a history of hospitalization 
due to aspiration pneumonia, the patients might have 
received antibiotic treatment.  The use of broad-
spectrum antibiotics for more than 2 days within 
the previous 90 days carried an increased risk of 
developing drug-resistant pathogens9.  It is, therefore, 
likely that patients with a history of hospitalization 
due to aspiration pneumonia might have a reduced 
response to SBT / ABPC or CTRX.  If patients 
are previously treated with antibiotics for aspiration 
pneumonia, broad-spectrum antibiotics should be 
recommended as initial antibiotic treatment.  This 
study aimed to investigate the risk factors of 
antibiotic treatment failure, other than those related 
to drug-resistant pathogens.  However, the risk factor 
for drug-resistant pathogens was extracted.  The 
reason was that some patients in this study presented 
with risk factors related to drug-resistant pathogens. 
Therefore, a history of hospitalization due to 
aspiration pneumonia might be associated with drug-
resistant pathogens.
　The risk of treatment failure increased 1.37-fold in 
Table 5.   Multivariable analysis of risk factors for antibiotic treatment failure including medications
Factors β OR 95％CI p-value
History of hospitalization due to aspiration pneumonia No vs Yes 0.58 1.79 1.10-2.90 0.019
No restriction of diet on admission No vs Yes 1.18 3.26 1.36-7.81 0.008
CRP (mg/dl) 5 mg/dl 0.24 1.28 1.10-1.47 0.001
Urinary disturbance agents other than overactive bladder agents No vs Yes 0.94 2.56 1.34-4.88 0.005
CRP, C-reactive protein; OR, odds ratio; CI, confidence interval.
Dementia, the severity of pneumonia, history of hospitalization due to aspiration pneumonia, CRP, Crea, no restriction 
of diet on admission, other agents affecting digestive organs, urinary disturbance agents other than overactive bladder 
agents, antacids, anti-tuberculous agents, sex hormone preparations, and other agents relating to blood and body fluids 
were incorporated into the multivariable analysis.
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patients with a higher level of severity of pneumonia. 
This was possibly owing to the worsening of the 
systemic dysfunction caused by an increase in the 
severity of pneumonia, progressing it to a state that 
could not be improved using antibiotic treatment. 
This study used the A-DROP score to assess the 
severity of pneumonia.  It has been previously 
reported that the survival rates in patients with mild, 
moderate, severe, and very severe pneumonia classified 
using A-DROP scores were 100％, 90.5％, 82.8％, 
and 71.7％, respectively24, suggesting that patients 
with higher A-DROP scores have extremely poor 
general conditions and poor prognosis.  In addition, 
as the components of A-DROP include dehydration 
and respiratory status, patients with increased severity 
of pneumonia have worsened dehydration and 
respiratory status.  Therefore, in addition to antibiotic 
treatment, systemic management such as water and 
respiratory management might be necessary during 
the initial treatment of patients with severe aspiration 
pneumonia.
　The risk of treatment failure was increased by 
1.26-fold with a 5 mg/dl increase in CRP.  CRP is 
a marker of inflammation and may correlate with 
the spread of inflamed tissue in the lungs.  Chest 
radiography findings have demonstrated that the 
inflammation in pneumonia increases with the 
increase in the width of the infiltrated area in the 
lung25.  Therefore, the inflammation of the lung tissue 
might be widespread when the CRP levels are high. 
Therefore, it is considered that patients with high 
CRP levels had strong lung tissue inflammation and, 
therefore, did not respond to SBT / ABPC or CTRX.
　Although drugs causing an increased risk of 
aspiration pneumonia have been reported previously26, 
there are no reports on the association between 
medications at admission and the risk factors for 
antibiotic treatment failure in patients with aspiration 
pneumonia.  Therefore, we investigated whether 
the medications at admission were associated with 
failure of initial antibiotic treatment for aspiration 
pneumonia.  The administration of urinary disturbance 
agents other than overactive bladder agents at the 
time of hospitalization resulted in a 2.56-fold increase 
in the risk of treatment failure.  Dry mouth is an 
adverse reaction of urinary disturbance agents other 
than overactive bladder agents.  Previous studies have 
shown that the presence of dry mouth significantly 
increases the incidence of aspiration pneumonia27, 
and carries a 2-fold higher risk of death owing 
to pneumonia28.  Therefore, the administration of 
urinary disturbance agents other than overactive 
bladder agents might increase the risks of death 
from pneumonia and also increase the risk of 
antibiotic treatment failure.  Older people tend to 
take multiple inappropriate medications inadvertently. 
If a patient is taking urinary disturbance agents 
other than overactive bladder agents at the 
time of hospitalization for aspiration pneumonia, 
discontinuation of the drug should be considered.  
　A limitation of this study is that the history 
of hospitalization due to aspiration pneumonia 
was recorded only if the patient was previously 
hospitalized in the surveyed hospital.  The study 
did not include a history of hospitalization at 
other hospitals.  Therefore, the rate of previous 
hospitalization due to aspiration pneumonia might be 
underreported.
Conclusion
　Our results suggested that no restriction of diet on 
admission, history of hospitalization due to aspiration 
pneumonia, severity of pneumonia, and increased 
CRP levels were risk factors associated with failure of 
initial antibiotic treatment in patients with aspiration 
pneumonia.  These factors will be useful for 
determining an effective initial treatment strategy for 
patients with aspiration pneumonia.  Furthermore, we 
expect that taking these factors into account will lead 
to an improvement in the management and treatment 
of patients with aspiration pneumonia.
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